e-Drug3D

1905

ENCORAFENIB

INN
ENCORAFENIB

cas 1269440-17-6

CLASS

ANTINEOPLASTIC
BRAF V600E KINASE INHIBITOR (KD=0.35 NANOMOLAR)
TREATMENT OF MELANOMA WITH A BRAF V600E OR V600K MUTATION
ALSO BINDS JNK1, JNK2, JNK3, LIMK1, LIMK2, MEK4, AND STK36 KINASES

ROUTE (list)

ORAL

ATC code

L01EC03

PK parameters

F 86 PERCENT
Tmax 2 HOUR
VD 164 LITER
Cl 14 LITER / HOUR
PPB 86 PERCENT
t1/2 3.5 HOUR

Solubility

INSOLUBLE IN WATER AT PH 3 AND HIGHER

Target

TARGET BRAF

DrugCentral

RAF proto-oncogene serine,threonine-protein kinase UNIPROT P04049 RAF1

Serine,threonine-protein kinase B-raf UNIPROT P15056 BRAF

Download SDF file

Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester

Formula:
C22H27ClFN7O4S

Calculated chemical properties:

MW 540.03
NB_atoms 36
XLogP 3.91
PSA 133.436
NB_HD 3
NB_HA 11
fsp3 0.36
Lipinski(0=no;1=yes) 0

FDA
NDA 210496 (label) INN (ENCORAFENIB) BRAFTOVI (ARRAY BIOPHARMA INC) APPROVAL= AP YEAR= 2018